Zusammenfassung
In dem Kapitel Maligne Tumoren der Mamma wird die Pathologie, Diagnostik und Therapie der Erkrankung umfassend beschrieben. Von der Klassifikation der Erkrankung bis hin zu modernen OP-Techniken und der Planung der Therapie in Bezug auf die unterschiedlichen intrinsischen Subtypen des Mammakarzinoms bietet dieses Kapitel einen guten Überblick über den Goldstandard in der Behandlung. Darüber hinaus werden zukunftsweisende Behandlungsstrategien und Medikationen aus der aktuellen Diskussion und Wissenschaft wiedergegeben. Das Kapitel eignet sich nicht nur für das Studium, sondern stellt ebenso ein Nachschlagewerk für den Arzt bzw. die Ärztin in der Weiterbildung dar. Die Literatur wurde umfangreich aktualisiert und bietet somit die Möglichkeit, in das tiefere Studium dieser Erkrankung einzusteigen.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsLiteratur
Aberzk WJ, Siver B, Henderson IC, Cady B, Harris JR (1986) The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 58:1214–1218
Adzersen KH, Gerhard I (2001) Phytoöstrogene und Brustkrebs – Senken Pflanzenöstrogene das Risiko? Geburtshilfe Frauenheilkd 61:234–241
Aebi S, Gelber S, Lang I, Anderson S, Robidoux A, Martin M et al (2012) Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial. Cancer Res 72 (24 Suppl) 96s (Abstr. S3-2)
Armstrong K, Moye E, Wiliams S, Berlin JA, Reynolds EE (2007) Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med 146:516–526
ATAC Trialists Group (2008) Effect of anastrazole and tamoxifen as adjuvant treatment for early breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53
Baselga J, Gelmon KA, Verma S et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138–1144
BIG 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757
Bilchert-Toft M, Smola MG, CataliottiL O’Higgins N (1997) Principles and guidelines for surgeons – management of symptomatic breast cancer. European Society of Surgical Oncology. Eur J Surg 23:101–109
Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124–1130
Bonnier P, Romain S, Dilhuydy JM et al (1997) Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Int J Cancer 4:720–727
Bratthauer GL, Tavassoli FA (2002) Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clincal implications. Virchows Arch 440:134–138
Brown JE, Coleman RE (2003) Metastatic bone disease: developing strategies to optimize management. Am J Can 2:269–281
Brufsky A, Rivera R, Hurvitz A et al (2010) Progression-free survival in patient subgroups in RIBBON-2, a phase II trial of chemotherapy plus or minus bevacizumab for second-line treatment of Her2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 28 (Suppl) Abstr. 1021
Buchholz TA, Katz A, Strom EA et al (2002) Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 53:880–888
Calabrese C, Distante V, Orzalesi L et al (2001) Immediate reconstruction with mammaplasty in conservative breast cancer treatment: long-term results. Focus Rec Breast Cancer Surg Osp Ital Chir 7:38–46
Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092
Coombes R, Kilburn L, Snowdown C (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup exemestane study): a randomised controlled trial. Lancet 369:559–570
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M. Piccart-Gebhart M et al (2017) St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer. An Oncol 28(8, 1 August):1700–1712 https://doi.org/10.1093/annonc/mdx308
Dunne C, Burke JP, Morrow M, Kell MR (2009) Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 27:1615–1620
Early Breast Cancer Trialists’ Collaborative Group (1995) Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. N Engl J Med 335:1444–1455
Early Breast Cancer Trialists’ Collaborative Group (1996) Ovarian ablation in early breast cancer. Overview of randomized trials. Lancet 348:1189–1198
Early Breast Cancer Trialists’ Collaborative Group (2000) Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet 355:1757–1770
Early Breast Cancer Trialists’ Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
Ellis MJ, Hayes DF, Lippmann ME (2000) Treatment of metastatic breast cancer. Cancer 2000:749–797
Faverly DR, Burgers L, Bult P, Holland R (1994) Three dimensional imaging of mammary ductal carcinoma in clinical implications. Semin Diagn Pathol 11:193–198
Fisher B, Anderson S (1994) Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. World J Surg 18:63–69
Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M (1981) The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic and nodal status in carcinoma of the breast cancer. Surg Gynecol Obstet 152:765–772
Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up a randomized trial comparing total mastectomy, lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241
Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31510 women. J Clin Oncol 16:3439–3460
Geyer C, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for her2-positive advanced breast cancer. N Engl J Med 355:2733–2743
Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569–575. https://doi.org/10.1001/jama.2011.90
Gnant M, Mlineritsch B, Stoeger H et al, Austrian Breast and Colorectal Cancer Study Group (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12(7):631–641 https://doi.org/10.1016/s1470-2045(11)70122-x. (Epub 2011 Jun 5)
Goldhirsch A, Wood W, Gelber R et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144
Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen for early-stage breast cancer. N Engl J Med 349:1793–1802
Guinee VF, Olsson H, Moller T et al (1994) Effect of pregnancy on prognosis for young women with breast cancer. Lancet 343:1587–1589
Haffty BG, Fischer D, Beinfield M, Mckhann C (1991) Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 21:293–298
Hartmann LC, Schaid DJ, Woods JE et al (1999) Efficacy of bilateral prophylactic mastectomy in women with family history of breast cancer. N Engl J Med 340:77–84
Henderson IC, Berry DA, Demetri GD et al (2001) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983
Hortobagyi GM, Ames FC, Buzdar AU et al (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507
Hoskin PJ, Yarnold JR, Roos DR, Bentzen S (2001) Second workshop on palliative radiotherapy and symptom control: radiotherapy for bone metastases. Clin Oncol 13:88–90
Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms (2012) AWMF-Register-Nummer: 032 – 045OL. Kurzversion 3.0. Juli 2012
Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrazole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462
Kaufmann M, Costa SD, Scharl A (Hrsg) (2003) Die Gynäkologie. Springer, Berlin
Keck C, Tempfer C (2002) Hormonersatztherapie bei Frauen nach Brustkrebserkrankung. Geburtshilfe Frauenheilkd 62:1053–1059
Keck C, Tempfer C (2003) Hormonsubstitution und Mammakarzinomscreening. Geburtshilfe Frauenheilkd 63:999–1003
Klijn JG, Blamey RW, Boccardo F et al (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343–353
Köchli OR, Sevin BU, Benz J, Petru E (1998) Gynäkologische Onkologie. Springer, Berlin
Koscielny S, Tubiana M (1999) The link between local recurrence and distant metastases in breast cancer. Int J Radiat Oncol Biol Phys 43:245–246
Kreipe HH (2012) Translationale Forschung und Diagnostik beim Mammakarzinom. Pathologe 33(Suppl 2):282–290
Kroman N, Wohlfahrt J, Andersen KW, Mouridsen HT, Westergaard T, Melbye M (1997) Time since childbirth and prognosis in primary breast cancer: population based study. Int J Cancer 72:720–727
Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14:609–618
Lagios MD, Westdahl PR, Margolin FR, Rose MR (1982) Ductal carcinoma in situ. Relationship or extent of noninvasive to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 50:1309–1314
Levine MN, Bramwell VH, Pritchard KI et al (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 16:2651–2658
LHRH-agonists in Early Breast Cancer Overview group (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369:1711–1723
Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastastic breast cancer. N Engl J Med 357:2666–2676
Moebus V, Jackisch C, Lueck HJ et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28:2874–2880
Niemeyer M, Paepke S, Schmied R et al (2009) Subcutaneous mastectomy including skin conservation of the nipple areola complex: broadening the indications. Cancer Res 69(Suppl) Abstr. 3107
Noguchi M, Fukushima W, Ohta N et al (1992) Oncological aspects of immediate breast reconstruction im mastectomy patients. J Surg Oncol 50:241–246
O’Shaughnessy J, Dieras V, Glaspy J et al (2009) Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer. Cancer Res 69(Suppl) Abstr. 207
Paradiso A, Schittuli F, Cellamare G et al (2001) Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferation, node-negative breast cancer. J Clin Oncol 19:3929–3937
Rebbeck TR, Levin AM, Eisen A et al (1999) Breast cancer risk after bilateral prophylactic oophorectomy BRCA1 mutation carriers. J Natl Cancer Inst 91:1475–1479
Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prevention and observation of surgical end points study group. N Engl J Med 346:1616–1622
Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98:229–238
Robson M, Im S, Senkus E, Xu B, Domchek S, Masuda N et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523–533
Schrag D, Kuntz KM, Garber JE, Weeks JC (1997) Decision analysis – effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 mutations. N Engl J Med 336:1465–1471
Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressmann PI (2000) Consensus Conference on the Treatment of In Situ Ductal Carcinoma in the Breast, April 22–25, 1999. Cancer 15:946–954
Silverstein MJ, Craig PH, Lagios MD et al (1996) Developing a prognostic index for ductal carcinoma in situ of breast. Cancer 78:1138–1140
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 3444:783–792
Smith I, Procter M, Gelber R et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 369:29–36
Solin L, Orel S, Hwang W et al (2008) Relationship of breast magnetic resonance imaging after breast conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 26:386–391
Stadtmauer EA, O’Neill A, Goldstein LJ et al (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 342:1069–1076
The ATAC Trialists Group (2003) Anastozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: results of the ATAC Trial Efficacy and Safety Update Analysis. Cancer 98:1802–1810
Thürlimann B (2005) BIG-1–98. A prospective randomized phase III study to evaluate letrozol as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast 14:4
Tran NV, Chang DW, Gupta A, Kroll SS, Robb GL (2001) Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy. Plast Reconstr Surg 108:78–82
Tutt A, Robson M, Garber J et al (2010) Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof of concept trial. Lancet 376:235–244
Vandeweyer E, Deraemaecker R, Nogaret JM, Hertens D (2000) Institution immediate breast reconstruction with implants and adjuvant chemotherapy: a good option? Eur J Cancer 36(Suppl 5):59
Vandeweyer E, Hertens D, Nogaret JM, Deraemaecker R (2001) Immediate breast reconstruction with saline filled implants: no Interference with the oncologic outcome? Plast Reconstr Surg 107:1409–1412
Van Teinhoven G, Voogd AC, Peterse JL et al (1999) Prognosis after treatment for loco-regional recurrence after mastectomy and breast-conserving therapy in two randomised studies (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish BREast Cancer Cooperative Group. Eur J Cancer 35:32–38
Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1232–1277
Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553
Voogd AC, Nielsen M, Peterse JL et al (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19:1688–1697
Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML (2000) Does locoregional radiation therapy improve survival in breast cancer? A metaanalysis. J Clin Oncol 18:1220–1229
Wittekind C (Hrsg) (2017) TNM Klassifikation maligner Tumoren, 8. Aufl. Wiley-VCH, Weinheim
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Schem, C., Jonat, W., Maass, N. (2019). Maligne Tumoren der Mamma. In: Petru, E., Fink, D., Köchli, O., Loibl, S. (eds) Praxisbuch Gynäkologische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57430-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-662-57430-0_1
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57429-4
Online ISBN: 978-3-662-57430-0
eBook Packages: Medicine (German Language)